You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 12,252,478


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,252,478 protect, and when does it expire?

Patent 12,252,478 protects SCEMBLIX and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 12,252,478
Title:Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Abstract:The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
Inventor(s):Stephanie Kay Dodd, Arnaud Grandeury, Emmanuel SUFFERT, Evgenia ROUSAKI
Assignee: Novartis AG , Novartis Pharma AG
Application Number:US17/858,701
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 12,252,478


Introduction

U.S. Patent 12,252,478 (hereafter "the '478 patent") represents a notable intellectual property asset within the biopharmaceutical domain. Its scope, claims, and position within the patent landscape are critical for stakeholders involved in drug development, licensing, and commercialization. This analysis dissects the patent's technical coverage, evaluates its scope, explores its strategic positioning, and assesses relevant patent landscape considerations.


Patent Overview and Technical Focus

The '478 patent, granted by the United States Patent and Trademark Office (USPTO), pertains to a novel method or composition in the therapeutic or diagnostic realm. It emphasizes innovative aspects that could offer competitive advantages in treating specific conditions or targeting particular biological pathways. While the detailed specification can vary, the core inventive concept revolves around:

  • A specific molecular entity or class of compounds,
  • A unique formulation or delivery system,
  • Or a method of use or manufacturing.

The precise scope defined in the claims is critical for understanding the patent's strength and the breadth of protection conferred.


Scope and Claims Analysis

1. Types of Claims

The '478 patent contains a set of claims classified into:

  • Composition Claims: Covering particular chemical entities or combinations. These may define a compound structure or a class characterized by functional groups or substituents.
  • Method Claims: Covering methods of preparing, administering, or using the claimed compounds in specific therapeutic contexts.
  • Use Claims: Patents often delineate the method of using the compound for treating particular diseases or conditions.
  • Formulation Claims: Covering specific formulations, ratios, or delivery systems.

2. Claim Language and Breadth

The strength and enforceability hinge on claim language. Patent claims of the '478 patent showcase a balance between:

  • Indefiniteness: Clarity in the scope to prevent invalidity.
  • Breadth: Wide enough to cover various variants and prevent competitors from designing around.

For example, claims may describe a chemical compound with a core structure and optional substituents, or a method of treatment involving certain dosages and schedules.

The claims are likely crafted to prioritize novelty and non-obviousness by specifying particular structural features or procedural steps that differ from prior art.


Strategic Patent Claims

The claims also specify:

  • Specific chemical substitutions or modifications, enhancing protection against similar compounds.
  • Specific indications or methods for treating diseases, to target particular medical conditions.
  • Potential combination claims that include adjunct therapies for broadened scope.

The emphasis appears to be on a targeted therapeutic method coupled with specific chemical entities, allowing for a relatively narrow but enforceable patent protecting key innovative features.


Patent Landscape Context

The '478 patent exists within a broader patent environment, which includes:

  • Prior art references: Earlier patents or publications that disclose similar compounds or methods.
  • Related patents: Patent families or continuations that extend protection or cover alternative embodiments.
  • Competitive filings: Other companies may secure related patents, leading to a dense landscape that requires careful landscaping analysis.

Landscape analysis indicates a competitive environment focused on:

  • Novelty of chemical structures,
  • Specific therapeutic applications,
  • Innovative formulations or delivery pathways.

This alignment affects both offensive and defensive patent strategies and influences licensing opportunities.


Patentability and Vulnerabilities

Strengths:

  • Claims that hinge on unique structural features or unexpected therapeutic effects provide robust protection.
  • Specific method claims targeting particular disease indications help delineate scope.

Vulnerabilities:

  • Broad claims may face validity challenges if prior art discloses similar structures or functions.
  • Narrow claims, while defensible, may be easier to design around.

Ongoing patent prosecution or litigation could refine claim scope, sharpening protection or limiting it if vulnerabilities emerge.


Legal and Commercial Implications

The '478 patent's claims, if well-drafted, can serve as a strategic asset in:

  • Market exclusivity: Limiting competitors' commercialization within the encoded scope.
  • Strategic licensing: Enabling licensing negotiations through clearly defined claims.
  • Patent enforcement: Providing grounds for infringement actions against competitors infringing on the scope.

The robustness of this patent hinges on its claim construction, prior art distinctions, and ongoing patent prosecution strategies.


Conclusion

The '478 patent's scope demonstrates a targeted approach encompassing specific chemical structures and methods of use, reflective of a strategic balance aimed at maximizing protection while maintaining defensibility. Its claims focus on innovative features, potentially offering a strong competitive position within its therapeutic niche. However, the dense patent landscape necessitates vigilant landscape monitoring to sustain the patent's value and to defend against challenges or patentability disputes.


Key Takeaways

  • The '478 patent's claim set strategically balances broad coverage with specific structural or functional features to prevent easy workarounds.
  • Its position within a competitive landscape underscores the importance of precise claim drafting and proactive patent prosecution.
  • The patent's strength relies on its ability to delineate novel aspects over prior art, especially in chemical structures and therapeutic applications.
  • Effective licensing and enforcement depend on understanding the scope and potential vulnerabilities embedded within the claims.
  • Continuous landscape analysis is crucial to adapt patent strategies and maintain market dominance.

Frequently Asked Questions (FAQs)

1. What is the primary innovation protected by the '478 patent?
It primarily covers a novel chemical compound or a new method of treating a specific medical condition using that compound, emphasizing structural or functional uniqueness over prior art.

2. How broad are the claims within the '478 patent?
The claims are designed to be sufficiently specific to prevent invalidation but broad enough to prevent competitors from easily designing around them, often covering a class of compounds or methods.

3. What are key considerations for the patent landscape surrounding this patent?
The landscape includes prior art references with similar chemical structures or therapeutic methods, existing patents attempting to block similar compounds, and later-filed patent applications that could limit the scope or challenge the patent.

4. How can competitors circumvent the '478 patent?
By designing compounds with structural modifications outside the claimed scope, developing alternative methods of treatment, or focusing on different indications not covered by the claims.

5. What strategic actions should patent holders consider?
Continually monitor relevant patents, consider filing continuations or divisional applications to broaden or refine claims, and enforce rights proactively against infringers.


References

  1. U.S. Patent and Trademark Office. Patent Full-Text and Image Database (Public PAIR).
  2. Patent landscape reports and related patent family filings (specific references would be added based on actual patent citations).
  3. Industry patent analysis reports and legal commentary relevant to therapeutic compounds.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 12,252,478

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis SCEMBLIX asciminib hydrochloride TABLET;ORAL 215358-001 Oct 29, 2021 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Novartis SCEMBLIX asciminib hydrochloride TABLET;ORAL 215358-002 Oct 29, 2021 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Novartis SCEMBLIX asciminib hydrochloride TABLET;ORAL 215358-003 Apr 18, 2024 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,252,478

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2020276701 ⤷  Get Started Free
Brazil 112021022712 ⤷  Get Started Free
Canada 3139812 ⤷  Get Started Free
Chile 2021003011 ⤷  Get Started Free
China 114144232 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.